In the last trading session, 2.38 million shares of the Summit Therapeutics Inc (NASDAQ:SMMT) were traded, and its beta was -1.05. Most recently the company’s share price was $19.95, and it changed around $0.17 or 0.86% from the last close, which brings the market valuation of the company to $14.82B. SMMT currently trades at a discount to its 52-week high of $36.91, offering almost -85.01% off that amount. The share price’s 52-week low was $6.78, which indicates that the current value has risen by an impressive 66.02% since then.
Summit Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended SMMT as a Hold, whereas 7 deemed it a Buy, and 1 rated it as Underweight. Summit Therapeutics Inc is expected to report earnings per share of -0.07 for the current quarter.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Instantly SMMT has showed a green trend with a performance of 0.86% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 23.03 on recent trading dayincreased the stock’s daily price by 13.37%. The company’s shares are currently up 11.80% year-to-date, but still down -7.47% over the last five days. On the other hand, Summit Therapeutics Inc (NASDAQ:SMMT) is -13.60% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $39.5, which translates to bulls needing to increase their stock price by 49.49% from its current value. Analyst projections state that SMMT is forecast to be at a low of $30 and a high of $44.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -10.52%. Summit Therapeutics Inc earnings are expected to increase by -30.60% in 2025, but the outlook is negative -23.77% per year for the next five years.
SMMT Dividends
Summit Therapeutics Inc’s next quarterly earnings report is expected to be released in July.
VANGUARD GROUP INC, with 1.2457% or 8.82 million shares worth $68.78 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
